D. E. Shaw & Co. Inc. Has $236,000 Holdings in Collegium Pharmaceutical Inc (NASDAQ:COLL)

Share on StockTwits

D. E. Shaw & Co. Inc. cut its holdings in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) by 86.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,936 shares of the specialty pharmaceutical company’s stock after selling 119,081 shares during the period. D. E. Shaw & Co. Inc. owned 0.05% of Collegium Pharmaceutical worth $236,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. First Quadrant L P CA lifted its position in Collegium Pharmaceutical by 87.2% during the 2nd quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 2,089 shares during the period. DekaBank Deutsche Girozentrale lifted its position in Collegium Pharmaceutical by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $221,000 after purchasing an additional 2,400 shares during the period. Northern Trust Corp lifted its position in Collegium Pharmaceutical by 1.1% during the 2nd quarter. Northern Trust Corp now owns 387,440 shares of the specialty pharmaceutical company’s stock valued at $5,095,000 after purchasing an additional 4,201 shares during the period. Bank of New York Mellon Corp lifted its position in Collegium Pharmaceutical by 2.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 189,543 shares of the specialty pharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 4,524 shares during the period. Finally, GSA Capital Partners LLP lifted its position in Collegium Pharmaceutical by 11.3% during the 2nd quarter. GSA Capital Partners LLP now owns 71,802 shares of the specialty pharmaceutical company’s stock valued at $944,000 after purchasing an additional 7,313 shares during the period. Institutional investors own 92.08% of the company’s stock.

Shares of NASDAQ:COLL opened at $11.79 on Friday. The firm’s 50 day simple moving average is $11.47 and its 200 day simple moving average is $12.46. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23. Collegium Pharmaceutical Inc has a fifty-two week low of $10.01 and a fifty-two week high of $19.83.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. Collegium Pharmaceutical’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period last year, the company posted ($0.40) EPS. Sell-side analysts predict that Collegium Pharmaceutical Inc will post -0.37 EPS for the current year.

A number of research analysts have issued reports on COLL shares. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 target price (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. Needham & Company LLC set a $33.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, September 27th. BidaskClub upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. William Blair reiterated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Tuesday, September 17th. Finally, ValuEngine upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $24.00.

In other Collegium Pharmaceutical news, Director David Hirsch sold 22,106 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total transaction of $257,534.90. Following the sale, the director now directly owns 64,223 shares in the company, valued at approximately $748,197.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the sale, the director now owns 132,069 shares in the company, valued at $1,487,096.94. The disclosure for this sale can be found here. Company insiders own 8.08% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

See Also: How are dividend achievers different from dividend aristocrats?

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.